News for Myriad Genetics, Inc. (MYD.DE)

On February 27, 2025, Myriad Genetics Inc (MYGN), a leader in molecular diagnostics and precision medicine, announced a strategic collaboration with Gabbi, a te

**media[550320]**

Myriad Genetics Inc (MYGN), a leader in genetic testing and precision medicine, announced its financial results for the fourth quarter and full-year ending Dece

Myriad Genetics Inc (MYGN), a prominent player in molecular diagnostics and precision medicine, announced on February 24, 2025, the appointment of Sam Raha as t

On February 24, 2025, Myriad Genetics Inc (MYGN), a leader in molecular diagnostic testing and precision medicine, announced a strategic collaboration with PATH

Revenue Growth: 11% increase in 2024 compared to 2023.Adjusted Gross Profit: Approximately $589 million in 2024.Adjusted EBITDA: $40 million in 2024.Adjusted E

Feb 24, 2025 / 09:30PM GMTOperator Good day, and thank you for standing by. Welcome to the Myriad Genetics fourth quarter 2024 financial earnings conference cal

Myriad Genetics, Inc. (NASDAQ:MYGN) Q4 2024 Results Conference Call February 24, 2025 4:30 PM ETCompany ParticipantsMatt Scalo - Senior Vice President of...

Quarterly Revenue: $211 million, slightly below the estimated $211.62 million, but up 7% year-over-year, driven by strong demand in Pharmacogenomics and Prenat

Appoints Sam Raha as CEO and Mark S. Verratti as COO Effective April 30, 2025 SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. ( MYGN

Highlights Fourth quarter 2024 revenue of $211 million, grew 7% year-over-year driven by continued demand for Pharmacogenomics (14%) and Prenatal (12%) testing

**media[548586]**

Management will participate in three upcoming investor healthcare conferences SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. ( MYGN

**media[533451]**

**media[532897]**

**media[527269]**

We recently compiled a list of the Billionaire Larry Robbins' Long-Term Stock Picks. In this article, we are going to take a look at where Myriad Genetics, Inc.

**media[522591]**

On January 21, 2025, Myriad Genetics Inc (MYGN), a leader in genetic testing and precision medicine, announced the results of a study demonstrating that the use